Home » Stocks » GNPX

Genprex, Inc. (GNPX)

Stock Price: $3.40 USD -0.42 (-10.99%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $3.48 +0.08 (2.35%) Apr 20, 7:42 PM
Market Cap 147.14M
Revenue (ttm) n/a
Net Income (ttm) -17.94M
Shares Out 35.52M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $3.40
Previous Close $3.82
Change ($) -0.42
Change (%) -10.99%
Day's Open 3.86
Day's Range 3.22 - 3.92
Day's Volume 1,979,440
52-Week Range 1.95 - 7.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemothe...

1 week ago - Proactive Investors

10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX)  presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...

Other stocks mentioned: ALT, AUIAF, AURQF, AUSAF, BABYF, CAAOF, CRTPF ...
1 week ago - Proactive Investors

AUSTIN, Texas--(BUSINESS WIRE)--Genprex collaborators report new, positive preclinical data for its lead drug candidate, REQORSA, at the 2021 AACR Annual Meeting.

1 week ago - Business Wire

Focused on developing life-changing therapies for patients with cancer and diabetes  Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with the ...

2 weeks ago - Proactive Investors

AUSTIN, Texas--(BUSINESS WIRE)--Genprex' EVP and Chief Operating Officer will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

2 weeks ago - Business Wire

Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in two ...

3 weeks ago - Proactive Investors

AUSTIN, Texas--(BUSINESS WIRE)--Preclinical Data for Genprex' TUSC2 Immunogene Therapy Will Be Featured in Two Presentations at the 2021 AACR Annual Meeting

3 weeks ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's President and CEO will present at the Virtual Oncology Investor Conference on March 29

3 weeks ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at upcoming investor conferences in March 2021.

1 month ago - Business Wire

Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stoc...

2 months ago - Proactive Investors

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

2 months ago - Business Wire

Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs.  Comprised of preeminent clinical specialists, the ...

2 months ago - Proactive Investors

AUSTIN, Texas--(BUSINESS WIRE)--Genprex forms a Clinical Advisory Board.

2 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.

2 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex issues January 2021 shareholder letter.

2 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on February 4 at the Virtual Investor Conference.

2 months ago - Business Wire

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued...

Other stocks mentioned: BEEM, BLNK, CELH, CODX, CRDF, GRWG, KIRK ...
2 months ago - Seeking Alpha

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.

2 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET

3 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing

3 months ago - Business Wire

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opport...

Other stocks mentioned: CRDF, NVAX, TRIL, VXRT
3 months ago - Benzinga

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces $12 million registered direct closing.

3 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...

3 months ago - Business Wire

Genprex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to data from the World Health Organization, cancer is currently the second l...

3 months ago - Benzinga

AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes clinical-grade manufacturing of lead drug candidate, REQORSA

3 months ago - Business Wire

Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes major manufacturing milestone with completion of technology transfer

4 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for Acclaim-1 clinical trial

4 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's COO will present on December 1 at the Diamond Equity Research Emerging Growth Invitational

4 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Thomas Gallagher will participate as a panelist at the NYC-based Life Sciences Summit

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--George Gittes, MD Joins Genprex's Scientific Advisory Board

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces new clinical trial branding for upcoming trials in non-small cell lung cancer

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex receives conditional FDA acceptance of proprietary name Reqorsa(TM) for lead drug candidate

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints Eric Chapdelaine to VP of Manufacturing

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Zooming with LD Micro virtual event

6 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Cell and Gene Meeting on the Mesa

6 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints new Vice President of Regulatory Affairs

7 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Chairman and CEO will present on September 1, 2020 at the LD 500 Virtual Conference

7 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will Present at the Proactive Investor Forum on August 4 at 1:40 p.m. ET

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex appears live on the Big Biz Show for a second time

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's collaborators at the University of Pittsburgh receive $2.5 million grant from the NIH to fund diabetes gene therapy study.

8 months ago - Business Wire

Shares of the micro-cap gene therapy company Genprex Inc (NASDAQ: GNPX) were advancing strongly on above-average volume Tuesday.

11 months ago - Benzinga

Shares of Genprex Inc. GNPX, +56.61% climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track design...

1 year ago - Market Watch

Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday.

1 year ago - Benzinga

When companies see their shares rise by 100% or more in a single day, it’s usually because of a buyout or an extremely positive change in a company’s future prospects.

1 year ago - 24/7 Wall Street

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Co...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial n...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope f...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial ...

1 year ago - GlobeNewsWire

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achieve...

1 year ago - GlobeNewsWire

About GNPX

Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle... [Read more...]

Industry
Biotechnology
IPO Date
Mar 29, 2018
CEO
J. Rodney Varner
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
GNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Genprex stock is "Strong Buy" and the 12-month stock price forecast is 6.67.

Price Target
$6.67
Analyst Consensus: Strong Buy